MINDCURE Launches “Desire Project” To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy Post published:September 27, 2021 Post category:Press Release
MINDCURE Signs Exclusive Digital Clinical Data Licensing Agreement with ATMA Journey Centers Post published:September 23, 2021 Post category:Press Release
MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry Post published:September 16, 2021 Post category:Press Release
MINDCURE Announces Financial Results for Fiscal 2021 Post published:August 31, 2021 Post category:Press Release
MINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital Therapeutics Platform to Partner Clinics in North America Post published:August 26, 2021 Post category:Press Release
MINDCURE Welcomes Dr. Ken Weingardt, Digital Therapy Visionary, as a Senior Clinical Technology Advisor to its Psychedelic Digital Therapeutics Team Post published:August 10, 2021 Post category:Press Release
MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research Post published:July 27, 2021 Post category:Press Release
MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company’s First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound Post published:July 13, 2021 Post category:Press Release
MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression Post published:June 17, 2021 Post category:Press Release
MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research Post published:June 3, 2021 Post category:Press Release